Clinical Outcomes of Recombinant Human-soluble Thrombomodulin Treatment for Disseminated Intravascular Coagulation in Solid Tumors - PubMed (original) (raw)

Review

. 2019 May;39(5):2259-2264.

doi: 10.21873/anticanres.13342.

Affiliations

• PMID: 31092417
• DOI: 10.21873/anticanres.13342

Review

Clinical Outcomes of Recombinant Human-soluble Thrombomodulin Treatment for Disseminated Intravascular Coagulation in Solid Tumors

Shinichiro Kashiwagi et al. Anticancer Res. 2019 May.

Abstract

Disseminated intravascular coagulation (DIC) that occurs during cancer therapy prevents continuation of therapy, contributing to a worse prognosis. While recombinant human-soluble thrombomodulin (rhTM), a new DIC drug, has occasionally shown its efficacy in DIC associated with infection and blood cancer, its efficacy in patients with solid tumors has been unproven. This review presents the results on the efficacy and safety of rhTM as a DIC drug in patients with solid tumors that have been confirmed by the clinical data of three previous reports. The number of cases in each study was 101, 123 and 40. The respective DIC resolution rate was 34.0%, 35.2% and 32.5%, and the 28-day survival rate was 55.4%, 52.0% and 40.0%. Although comparison with other anti-DIC therapies is required, rhTM therapy is considered one of the treatment options of DIC in patients with solid tumors.

Keywords: Recombinant human-soluble thrombomodulin; disseminated intravascular coagulation; review; solid tumor; tissue factor.

Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

PubMed Disclaimer

Similar articles

• Retrospective analysis on the clinical outcomes of recombinant human soluble thrombomodulin for disseminated intravascular coagulation syndrome associated with solid tumors.
  Ouchi K, Takahashi S, Chikamatsu S, Ito S, Takahashi Y, Kawai S, Okita A, Kasahara Y, Okada Y, Imai H, Komine K, Saijo K, Takahashi M, Shirota H, Takahashi M, Gamoh M, Ishioka C. Ouchi K, et al. Int J Clin Oncol. 2018 Aug;23(4):790-798. doi: 10.1007/s10147-018-1261-z. Epub 2018 Mar 7. Int J Clin Oncol. 2018. PMID: 29511940 Free PMC article.
• Efficacy and safety of recombinant human soluble thrombomodulin in patients with sepsis-induced disseminated intravascular coagulation - A meta-analysis.
  Kato H, Hagihara M, Asai N, Umemura T, Hirai J, Mori N, Yamagishi Y, Iwamoto T, Mikamo H. Kato H, et al. Thromb Res. 2023 Jun;226:165-172. doi: 10.1016/j.thromres.2023.05.009. Epub 2023 May 9. Thromb Res. 2023. PMID: 37182388
• A retrospective comparative study of recombinant human thrombomodulin and gabexate mesilate in sepsis-induced disseminated intravascular coagulation patients.
  Takazono T, Nakamura S, Imamura Y, Yoshioka S, Miyazaki T, Izumikawa K, Sawai T, Matsuo N, Yanagihara K, Suyama N, Kohno S. Takazono T, et al. J Infect Chemother. 2014 Aug;20(8):484-8. doi: 10.1016/j.jiac.2014.04.010. Epub 2014 May 21. J Infect Chemother. 2014. PMID: 24855912
• Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis.
  Yamakawa K, Aihara M, Ogura H, Yuhara H, Hamasaki T, Shimazu T. Yamakawa K, et al. J Thromb Haemost. 2015 Apr;13(4):508-19. doi: 10.1111/jth.12841. Epub 2015 Mar 5. J Thromb Haemost. 2015. PMID: 25581687 Review.
• Recombinant human soluble thrombomodulin and short-term mortality of infection patients with DIC: a meta-analysis.
  Zhang C, Wang H, Yang H, Tong Z. Zhang C, et al. Am J Emerg Med. 2016 Sep;34(9):1876-82. doi: 10.1016/j.ajem.2016.06.001. Epub 2016 Jun 3. Am J Emerg Med. 2016. PMID: 27452884 Review.

Cited by

• Efficacy and Safety of FOLFOX in Advanced Gastric Cancer Initially Presenting With Disseminated Intravascular Coagulation.
  Takahashi N, Ando T, Motoo I, Sakumura M, Ueda Y, Kajiura S, Nakashima K, Hosokawa A, Ueda A, Suzuki N, Nakaya A, Yasuda I. Takahashi N, et al. In Vivo. 2022 Sep-Oct;36(5):2447-2452. doi: 10.21873/invivo.12979. In Vivo. 2022. PMID: 36099124 Free PMC article.
• Severe thrombocytopenia and anemia as an initial presentation of breast cancer: A case report.
  Otsubo R, Yano H, Itonaga H, Iwasaki K, Segawa K, Nagayasu T. Otsubo R, et al. Clin Case Rep. 2022 Dec 20;10(12):e6762. doi: 10.1002/ccr3.6762. eCollection 2022 Dec. Clin Case Rep. 2022. PMID: 36545558 Free PMC article.
• C-type lectin domain group 14 proteins in vascular biology, cancer and inflammation.
  Khan KA, McMurray JL, Mohammed F, Bicknell R. Khan KA, et al. FEBS J. 2019 Sep;286(17):3299-3332. doi: 10.1111/febs.14985. Epub 2019 Jul 29. FEBS J. 2019. PMID: 31287944 Free PMC article. Review.
• Antithrombin use and mortality in patients with stage IV solid tumor-associated disseminated intravascular coagulation: a nationwide observational study in Japan.
  Taniguchi K, Ohbe H, Yamakawa K, Matsui H, Fushimi K, Yasunaga H. Taniguchi K, et al. BMC Cancer. 2020 Sep 9;20(1):867. doi: 10.1186/s12885-020-07375-2. BMC Cancer. 2020. PMID: 32907555 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • HighWire